-
monoclonal antibody used as a
treatment for cancer. It was
originated by
GlycArt Biotechnology AG and
developed by Roche.[citation needed] As of 2015, obinutuzumab...
- was the
basis of
GlycArt Biotechnology.
Roche acquired GlycArt in 2005 in
order to
acquire technology to
afucosylate antibodies.
GlycArt Biotechnology had...
-
manufacture Oseltamivir. Also in 2005,
Roche acquired the
Swiss company GlycArt Biotechnology in
order to
acquire technology to
afucosylate antibodies;...
- 2008
Genentech entered into a
collaboration with
Roche and its
subsidiary GlycArt to
develop obinutuzumab. In
February 2010
Genentech entered into a collaboration...
- 24 (1): 177. doi:10.1186/s13063-023-07210-6. PMC 10000352. PMID 36899430.
Art. No. 177.
Nelson A (31
August 2022).
Khatri M (ed.). "Does Milk
Thistle Help...
- agglutinative, glue, glutelin, gluten, glutinosity, glutinous,
nonagglutinative glyc-
sweet Gr**** γλυκύς (glukús) glycogen, glycogenesis, glycogenolysis, glycolipid...
